Nifty
:
24631.30
Sensex
:
80597.66
11.95 (0.05%)
57.75 (0.07%)
Nifty
Sensex
:
:
24631.30
80597.66
11.95 (0.05%)
57.75 (0.07%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
1641.40
14-Aug-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1639.8
  •  1651.1
  •  1632.2
  •  1639.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1738094
  •  2849989291.3
  •  1960.35
  •  1553.05

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,94,114.76
  • 38.00
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,84,652.77
  • 0.97%
  • 5.29

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 2.07%
  • 5.34%
  • FII
  • DII
  • Others
  • 17.26%
  • 17.83%
  • 3.02%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.46
  • 9.44
  • 6.21

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.34
  • 12.24
  • 5.42

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.19
  • 30.28
  • 8.70

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 38.96
  • 40.14
  • 39.20

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.99
  • 4.63
  • 5.30

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.15
  • 21.11
  • 23.27

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
39.9
45.6
52.14
59.05
P/E Ratio
41.14
36.00
31.48
27.80
Revenue
47758
52041
57444
63114
EBITDA
12987
15086
15995
18055
Net Income
9576
10929
12543
14215
ROA
11.5
12.3
12
12.9
P/B Ratio
16.62
5.45
4.84
4.28
ROE
16.01
16.09
16.4
16.55
FCFF
10426
12589
9716
12271
FCFF Yield
2.76
3.34
2.57
3.25
Net Debt
-15832
-22626
-27853
-36929
BVPS
98.75
301
339.09
383.24

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
13,851.40
12,652.75
9.47%
12,958.84
11,982.90
8.14%
13,675.46
12,380.70
10.46%
13,291.39
12,192.41
9.01%
Expenses
9,778.78
9,045.13
8.11%
9,533.99
8,947.75
6.55%
9,666.44
9,028.43
7.07%
9,480.52
9,013.03
5.19%
EBITDA
4,072.62
3,607.62
12.89%
3,424.85
3,035.15
12.84%
4,009.02
3,352.27
19.59%
3,810.87
3,179.38
19.86%
EBIDTM
29.40%
28.51%
26.43%
25.33%
29.32%
27.08%
28.67%
26.08%
Other Income
693.50
532.55
30.22%
904.11
605.94
49.21%
465.62
374.76
24.24%
482.09
293.61
64.19%
Interest
74.80
61.54
21.55%
49.14
73.57
-33.21%
51.51
34.73
48.32%
69.17
49.29
40.33%
Depreciation
700.55
655.13
6.93%
663.79
650.36
2.07%
630.56
622.14
1.35%
625.91
632.82
-1.09%
PBT
3,172.77
3,423.50
-7.32%
3,254.35
2,815.52
15.59%
3,476.40
3,000.35
15.87%
3,597.88
2,790.88
28.92%
Tax
870.15
552.25
57.56%
1,093.71
148.93
634.38%
558.86
432.32
29.27%
567.21
390.10
45.40%
PAT
2,302.62
2,871.25
-19.80%
2,160.64
2,666.59
-18.97%
2,917.54
2,568.03
13.61%
3,030.67
2,400.78
26.24%
PATM
16.62%
22.69%
16.67%
22.25%
21.33%
20.74%
22.80%
19.69%
EPS
9.50
11.82
-19.63%
8.96
11.06
-18.99%
12.10
10.52
15.02%
12.67
9.90
27.98%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
53,777.09
52,578.44
48,496.85
43,885.68
38,654.49
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
Net Sales Growth
9.28%
8.42%
10.51%
13.53%
15.39%
2.01%
12.98%
10.03%
-15.63%
11.38%
 
Cost Of Goods Sold
10,886.69
10,747.36
10,662.61
10,662.16
10,351.54
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
Gross Profit
42,890.40
41,831.08
37,834.24
33,223.52
28,302.95
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
GP Margin
79.76%
79.56%
78.01%
75.70%
73.22%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
Total Expenditure
38,459.73
37,492.28
35,747.77
32,298.12
28,772.68
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
Power & Fuel Cost
-
750.40
760.78
830.05
702.78
627.09
621.89
613.60
559.97
525.09
545.44
% Of Sales
-
1.43%
1.57%
1.89%
1.82%
1.87%
1.89%
2.11%
2.12%
1.68%
1.94%
Employee Cost
-
9,973.12
9,429.06
8,296.03
7,300.83
6,862.23
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
% Of Sales
-
18.97%
19.44%
18.90%
18.89%
20.49%
19.38%
20.53%
20.32%
15.66%
16.98%
Manufacturing Exp.
-
2,261.24
2,186.62
1,936.77
1,880.71
1,723.78
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
% Of Sales
-
4.30%
4.51%
4.41%
4.87%
5.15%
5.15%
6.48%
6.92%
4.13%
5.05%
General & Admin Exp.
-
5,646.06
5,252.93
4,256.12
3,270.55
3,179.45
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
% Of Sales
-
10.74%
10.83%
9.70%
8.46%
9.49%
10.17%
9.39%
10.84%
9.95%
10.52%
Selling & Distn. Exp.
-
6,576.86
5,780.26
5,226.24
4,096.33
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
% Of Sales
-
12.51%
11.92%
11.91%
10.60%
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
Miscellaneous Exp.
-
1,537.24
1,675.51
1,090.75
1,169.94
843.83
963.29
1,107.57
1,047.60
1,106.04
2,262.35
% Of Sales
-
2.92%
3.45%
2.49%
3.03%
2.52%
2.93%
3.81%
3.97%
3.53%
6.49%
EBITDA
15,317.36
15,086.16
12,749.08
11,587.56
9,881.81
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
EBITDA Margin
28.48%
28.69%
26.29%
26.40%
25.56%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
Other Income
2,545.32
2,150.57
1,628.24
693.75
1,437.42
859.17
651.59
1,059.44
912.08
1,030.20
658.25
Interest
244.62
231.36
238.47
172.00
127.35
141.43
302.73
555.25
517.57
399.80
523.24
Depreciation
2,620.81
2,575.39
2,556.64
2,529.43
2,143.74
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
PBT
13,501.40
14,429.98
11,582.21
9,579.88
9,048.14
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
Tax
3,089.93
2,772.03
1,439.45
847.59
1,075.50
514.69
822.80
600.88
911.04
1,211.57
913.77
Tax Rate
22.89%
20.16%
12.98%
9.01%
24.00%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
PAT
10,411.47
10,944.39
9,614.79
8,521.48
3,289.27
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
PAT before Minority Interest
10,386.41
10,980.10
9,648.44
8,560.84
3,405.82
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
Minority Interest
-25.06
-35.71
-33.65
-39.36
-116.55
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
PAT Margin
19.36%
20.82%
19.83%
19.42%
8.51%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
PAT Growth
-0.91%
13.83%
12.83%
159.07%
12.79%
-22.85%
41.73%
25.73%
-69.50%
53.04%
 
EPS
43.39
45.61
40.07
35.52
13.71
12.15
15.75
11.12
8.84
28.99
18.94

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
72,218.02
63,666.75
55,995.38
48,011.22
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
Share Capital
239.93
239.93
239.93
239.93
239.93
239.93
239.93
239.93
239.93
240.66
Total Reserves
71,978.09
63,426.82
55,755.45
47,771.29
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
Non-Current Liabilities
-2,987.13
-2,714.34
-1,997.80
-1,316.37
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
Secured Loans
0.00
0.00
0.00
0.00
7.83
6.18
109.47
217.69
185.59
7.73
Unsecured Loans
2.52
1.33
0.00
229.92
646.88
2,022.74
1,413.14
1,554.40
1,250.49
3,102.57
Long Term Provisions
473.80
413.89
342.91
369.07
327.12
511.00
430.39
404.46
1,211.11
1,895.86
Current Liabilities
18,194.21
16,983.77
19,906.38
17,208.45
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
Trade Payables
6,184.34
5,653.30
5,681.52
4,489.76
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
Other Current Liabilities
3,254.45
2,716.85
2,603.51
2,926.73
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
Short Term Borrowings
1,867.11
2,844.36
5,958.26
468.52
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
Short Term Provisions
6,888.31
5,769.26
5,663.09
9,323.44
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
Total Liabilities
87,693.03
81,395.37
77,224.05
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
Net Block
22,586.28
23,248.15
24,065.44
22,665.16
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
Gross Block
45,949.61
44,320.48
43,099.95
38,707.36
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
Accumulated Depreciation
23,363.33
21,072.33
19,034.51
16,042.20
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
Non Current Assets
35,068.56
37,921.02
37,341.33
32,093.59
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
Capital Work in Progress
6,643.96
5,353.88
4,973.16
1,286.80
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
Non Current Investment
4,697.70
6,441.23
5,451.73
5,214.65
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
Long Term Loans & Adv.
1,016.49
2,784.59
2,757.87
2,880.86
4,061.34
4,104.48
3,848.29
6,052.85
3,844.04
2,322.87
Other Non Current Assets
124.13
93.17
93.13
46.12
4.67
5.53
21.96
50.21
682.18
953.34
Current Assets
52,594.06
43,433.11
39,861.94
34,864.60
30,442.08
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
Current Investments
13,656.10
8,584.54
9,372.61
7,633.94
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
Inventories
10,243.33
9,868.29
10,513.05
8,925.13
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
Sundry Debtors
13,046.11
11,249.37
11,438.51
10,484.59
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
Cash & Bank
11,331.62
10,520.68
5,770.29
5,033.35
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
Other Current Assets
4,316.90
755.99
745.91
775.01
2,808.09
2,973.02
3,072.69
2,919.93
3,546.51
2,847.64
Short Term Loans & Adv.
3,692.36
2,454.24
2,021.57
2,012.58
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
Net Current Assets
34,399.85
26,449.34
19,955.56
17,656.15
14,296.45
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
Total Assets
87,662.62
81,354.13
77,203.27
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
14,072.09
12,134.98
4,959.33
8,984.54
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
PBT
13,752.13
11,087.89
9,408.43
4,481.32
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
Adjustment
1,120.36
1,554.40
2,722.56
1,974.95
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
Changes in Working Capital
-323.56
1,062.13
-5,661.82
1,559.05
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
Cash after chg. in Working capital
14,548.93
13,704.42
6,469.17
8,015.32
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-476.84
-1,569.44
-1,509.84
969.22
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5,306.16
-690.20
-7,943.68
-5,724.74
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
Net Fixed Assets
-548.72
-420.26
-573.97
-1,120.95
-8,061.35
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
Net Investments
19.86
183.27
2,935.63
-11.67
1,824.52
542.39
451.15
978.04
3,038.39
3,504.47
Others
-4,777.30
-453.21
-10,305.34
-4,592.12
6,773.05
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
Cash from Financing Activity
-7,905.82
-6,710.16
2,376.07
-5,193.46
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
Net Cash Inflow / Outflow
860.11
4,734.62
-608.28
-1,933.66
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
Opening Cash & Equivalents
9,285.65
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
Closing Cash & Equivalent
10,268.77
9,285.65
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
301.00
265.36
233.38
200.11
193.65
188.66
172.59
159.69
152.70
137.03
ROA
12.99%
12.17%
11.88%
5.20%
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
ROE
16.16%
16.13%
16.46%
7.21%
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
ROCE
19.89%
17.60%
17.24%
9.28%
5.68%
10.07%
8.68%
8.40%
0.00%
18.64%
Fixed Asset Turnover
1.16
1.11
1.07
1.81
1.74
1.78
1.92
1.99
1.29
1.34
Receivable days
84.33
85.38
91.17
53.09
54.88
56.22
54.10
53.53
83.25
76.12
Inventory Days
69.81
76.70
80.83
48.68
50.10
48.40
47.84
48.88
78.98
77.46
Payable days
201.01
194.01
174.10
149.21
158.71
152.86
77.81
90.19
85.47
75.24
Cash Conversion Cycle
-46.88
-31.93
-2.10
-47.44
-53.73
-48.24
24.13
12.23
76.75
78.34
Total Debt/Equity
0.03
0.04
0.11
0.02
0.08
0.18
0.25
0.27
0.27
0.26
Interest Cover
60.44
47.50
55.70
36.19
20.79
17.55
7.86
7.72
23.63
13.56

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Sun Pharmaceutical Industries reports 20% fall in Q1 consolidated net profit
    31st Jul 2025, 16:30 PM

    Total consolidated income of the company increased by 8.57% at Rs 14315.86 crore for Q1FY26

    Read More
  • Sun Pharma incorporates subsidiary company in China
    18th Jul 2025, 09:30 AM

    Newly set up company will do localization of products which would be produced at prospective partners in China for sales locally

    Read More
  • Sun Pharmaceutical Industries launches LEQSELVI in U.S.
    15th Jul 2025, 10:23 AM

    With limited treatment options available to people living with severe alopecia areata in the U.S., the need for innovative therapies such as LEQSELVI remains critically important

    Read More
  • Sun Pharma’s partner withdraws application for marketing authorization to EMA for Nidlegy
    25th Jun 2025, 12:10 PM

    Sun Pharmaceutical Industries’ partner Philogen S.p.A has voluntarily withdrawn the application for marketing authorization to the European Medicines Agency for Nidlegy

    Read More
  • USFDA conducts GMP inspection of Sun Pharma’s Halol facility
    14th Jun 2025, 10:09 AM

    At the conclusion of the inspection, the USFDA issued a Form-483, with 8 observations

    Read More
  • Sun Pharmaceutical Industries to invest up to $25 milion in Pharmazz Inc
    26th May 2025, 10:23 AM

    The company has entered into an agreement with US based Pharmazz Inc

    Read More
  • Sun Pharmaceutical Industries reports 19% fall in Q4 consolidated net profit
    23rd May 2025, 16:14 PM

    The total consolidated income of the company increased by 7.81% at Rs 13571.71 crore for Q4FY25

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.